Xbrane and Stada have announced that the European Commission has granted marketing authorisation for biosimilar candidate, Ximluci – also known as ranibizumab – which also references Lucentis.
Bad Vilbel; Solna – 16 September 2022 – Partners STADA Arzneimittel AG and Xbrane Biopharma AB (Nasdaq Stockholm: XBRANE) announce that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Ximluci®, a biosimilar candidate referencing Lucentis® (ranibizumab).
Selexis and Generium shared that they have launched Genolar, a biosimilar for omalizumab (Xolair) on the Russian market for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria for patients aged 6 years and up.
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol)1.
Xbrane Biopharma AB (publ) (”Xbrane” eller ”Bolaget”) (Nasdaq Stockholm: XBRANE), a leading biosimilar developer, has announced the initiation of developing two new biosimilar candidates referencing Keytruda® and Darzalex® respectively. Together with the continued development of Xdivane™, a biosimilar candidate referencing Opdivo®, this forms an oncology biosimilar portfolio addressing €23 billion of combined annual reference product sales. Due to the announcement, Xbrane will host a videoconference tomorrow Tuesday December 14th, 11.00-11.45, registration in the link below.